文献速递细菌感染、耐药与抗菌药物医院感染防控

头孢地尔对比高剂量延长输注美罗培南治疗革兰阴性医院获得性肺炎:APEKS-NP随机双盲3期非劣效试验

Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial.
PubMed 文献 · Lancet Infect Dis · 2020-10-12

BACKGROUND: Nosocomial pneumonia due to multidrug-resistant Gram-negative pathogens poses an increasing challenge. We compared the efficacy and safety of cefiderocol versus high-dose, extended-infusion meropenem for adults with nosocomial pneumonia.…

要点

  • 头孢地尔2 g每8小时对革兰阴性医院获得性肺炎第14天全因死亡率非劣于高剂量延长输注美罗培南。
  • 两组治疗中出现的不良事件发生率相近,因药物相关不良事件停药者均少见。
  • 结果提示头孢地尔可作为医院获得性肺炎的潜在治疗选择,包括多重耐药革兰阴性菌所致者。

核心结论

  • 头孢地尔在革兰阴性医院获得性肺炎患者第14天全因死亡率方面非劣于高剂量延长输注美罗培南,耐受性相似。
  • 结果提示头孢地尔是医院获得性肺炎的潜在治疗选择,包括多重耐药革兰阴性菌所致者。

研究设计与样本

  • 随机、双盲、平行组、3期非劣效试验,在亚洲、欧洲和美国17个国家76个中心开展(APEKS-NP)。
  • 纳入18岁及以上医院获得性、呼吸机相关或医疗相关革兰阴性肺炎成人患者,1:1随机分组。
  • 头孢地尔2 g或美罗培南2 g每8小时静脉输注3小时,疗程7–14天,均联合开放标签利奈唑胺600 mg每12小时至少5天。
  • 按感染类型和APACHE II评分(≤15和≥16)随机化分层;主要终点为改良意向治疗人群第14天全因死亡率。

主要发现

  • 改良意向治疗人群292例中251例(86%)有合格基线革兰阴性病原体,包括肺炎克雷伯菌92例(32%)、铜绿假单胞菌48例(16%)、鲍曼不动杆菌47例(16%)、大肠埃希菌41例(14%)。
  • 142例(49%)APACHE II评分≥16,175例(60%)接受机械通气,199例(68%)随机化时在重症监护病房。
  • 治疗中出现的不良事件头孢地尔组130/148例(88%)、美罗培南组129/150例(86%);最常见者分别为尿路感染(23/148,16%)和低钾血症(23/150,15%)。

关键数值与推荐

  • 给药方案:头孢地尔2 g或美罗培南2 g每8小时静脉输注3小时,疗程7–14天,均联合利奈唑胺600 mg每12小时至少5天。

临床怎么用

  • 对革兰阴性医院获得性、呼吸机相关或医疗相关肺炎成人患者,可考虑头孢地尔2 g每8小时静脉输注3小时、疗程7–14天作为治疗选择。
  • 研究中所有患者均联合利奈唑胺600 mg每12小时至少5天以覆盖革兰阳性菌,临床决策需结合本地耐药流行病学。
  • 头孢地尔可作为多重耐药革兰阴性菌所致医院获得性肺炎的潜在选项。

局限性

  • 主要终点为第14天全因死亡率,随访至研究结束评估安全性,未报告更长期临床结局。
  • 改良意向治疗人群排除了革兰阳性单一微生物感染患者,结论适用人群受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Nosocomial pneumonia due to multidrug-resistant Gram-negative pathogens poses an increasing challenge. We compared the efficacy and safety of cefiderocol versus high-dose, extended-infusion meropenem for adults with nosocomial pneumonia. METHODS: We did a randomised, double-blind, parallel-group, phase 3, non-inferiority trial in 76 centres in 17 countries in Asia, Europe, and the USA (APEKS-NP). We enrolled adults aged 18 years and older with hospital-acquired, ventilator-associated, or health-care-associated Gram-negative pneumonia, and randomly assigned them (1:1 by interactive response technology) to 3-h intravenous infusions of either cefiderocol 2 g or meropenem 2 g every 8 h for 7-14 days. All patients also received open-label intravenous linezolid (600 mg every 12 h) for at least 5 days. An unmasked pharmacist prepared the assigned treatments; investigators and patients were masked to treatment assignment. Only the unmasked pharmacist was aware of the study drug assignment for the infusion bags, which were administered in generic infusion bags labelled with patient and study site identification numbers. Participants were stratified at randomisation by infection type and Acute Physiology and Chronic Health Evaluation II (APACHE II) score (≤15 and ≥16). The primary endpoint was all-cause mortality at day 14 in the modified intention-to-treat (ITT) population (ie, all patients receiving at least one dose of study drug, excluding patients with Gram-positive monomicrobial infections). The analysis was done for all patients with known vital status. Non-inferiority was concluded if the upper bound of the 95% CI for the treatment difference between cefiderocol and meropenem groups was less than 12·5%. Safety was investigated to the end of the study in the safety population, which included all patients who received at least one dose of study drug. This trial is registered with ClinicalTrials.gov, NCT03032380, and EudraCT, 2016-003020-23. FINDINGS: Between Oct 23, 2017, and April 14, 2019, we randomly assigned 148 participants to cefiderocol and 152 to meropenem. Of 292 patients in the modified ITT population, 251 (86%) had a qualifying baseline Gram-negative pathogen, including Klebsiella pneumoniae (92 [32%]), Pseudomonas aeruginosa (48 [16%]), Acinetobacter baumannii (47 [16%]), and Escherichia coli (41 [14%]). 142 (49%) patients had an APACHE II score of 16 or more, 175 (60%) were mechanically ventilated, and 199 (68%) were in intensive care units at the time of randomisation. All-cause mortality at day 14 was 12·4% with cefiderocol (18 patients of 145) and 11·6% with meropenem (17 patients of 146; adjusted treatment difference 0·8%, 95% CI -6·6 to 8·2; p=0·002 for non-inferiority hypothesis). Treatment-emergent adverse events were reported in 130 (88%) of 148 participants in the cefiderocol group and 129 (86%) of 150 in the meropenem group. The most common treatment-emergent adverse event was urinary tract infection in the cefiderocol group (23 patients [16%] of 148) and hypokalaemia in the meropenem group (23 patients [15%] of 150). Two participants (1%) of 148 in the cefiderocol group and two (1%) of 150 in the meropenem group discontinued the study because of drug-related adverse events. INTERPRETATION: Cefiderocol was non-inferior to high-dose, extended-infusion meropenem in terms of all-cause mortality on day 14 in patients with Gram-negative nosocomial pneumonia, with similar tolerability. The results suggest that cefiderocol is a potential option for the treatment of patients with nosocomial pneumonia, including those caused by multidrug-resistant Gram-negative bacteria. FUNDING: Shionogi.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Wunderink RG, Matsunaga Y, Ariyasu M, et al. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2020. PMID: 33058798. doi:10.1016/S1473-3099(20)30731-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。